Baxdrostat - CinCor Pharma
Alternative Names: CIN-107Latest Information Update: 14 May 2024
At a glance
- Originator Roche
- Developer AstraZeneca; CinCor Pharma; CinRx Pharma
- Class Amides; Antihypertensives; Antisecretories; Isoquinolines; Small molecules
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertension; Renal failure
- Phase II Hyperaldosteronism
- Phase I Spinal cord disorders
Most Recent Events
- 16 Apr 2024 AstraZeneca initiates the phase I trial (In volunteers, Combination therapy) (NCT06357520)
- 16 Apr 2024 AstraZeneca initiates the phase I trial (In volunteers, Monotherapy) (NCT06357520)
- 10 Apr 2024 AstraZeneca plans a phase I pharmacokinetics trial (In volunteers, Monotherapy, Combination therapy) (PO) (NCT06357520)